<DOC>
	<DOCNO>NCT02899156</DOCNO>
	<brief_summary>Delirium within intensive care unit ( ICU ) associate poor outcome increase mortality , ICU hospital length stay ( LOS ) , time mechanical ventilation . Benzodiazepine ( BZD ) exposure independent risk factor development delirium . Reversal hypoactive delirium represent potential opportunity reduce duration delirium subsequent complication . This single-center randomized , double-blind , placebo-controlled study critically ill adult patient benzodiazepine-associated hypoactive delirium . The hypothesis flumazenil continuous infusion revers hypoactive delirium associate BZD toxicity thereby reduce duration delirium ICU LOS .</brief_summary>
	<brief_title>Flumazenil Hypoactive Delirium Secondary Benzodiazepine Toxicity</brief_title>
	<detailed_description>Benzodiazepines commonly use discomfort , anxiety , agitation , alcohol withdrawal syndrome ( AWS ) ICU . End organ dysfunction extend exposure increase risk complication associate BZDs , include increase ICU LOS , time mechanical ventilation , mortality . Flumazenil 1 , 4-imidazobenzodiazepine competitive antagonist benzodiazepine bind site weak intrinsic partial agonistic activity GABA receptor . Multiple study confirm safety effectiveness flumazenil reversal sedation . Pilot study demonstrate safe reversal over-sedation statistically significant improvement patient cooperation time extubation . The current standard suspect BZD-associated hypoactive delirium cessation benzodiazepine administration supportive care . The role continuous infusion flumazenil rapid sustain reversal hypoactive delirium ICU evaluate prospectively therefore remain poorly define .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Flumazenil</mesh_term>
	<criteria>critically ill adult RASS score 3 +1 CAMICU positive benzodiazepine therapy within previous 12 hour Contraindications flumazenil include hypersensitivity receipt benzodiazepine control potentially lifethreatening condition ( eg , control intracranial pressure status epilepticus ) active seizure disorder current anticonvulsant therapy history seizure disorder . Seizures secondary alcohol withdrawal NOT exclude history traumatic brain injury complicate seizure acute episode ( within prior 30 day ) severe traumatic brain injury history structural lesion ( e.g . subarachnoid hemorrhage , cerebrovascular accident , intraparenchymal hemorrhage ) complicate seizure acute episode ( within prior 14 day ) structural lesion ( e.g . subarachnoid hemorrhage , cerebrovascular accident , intraparenchymal hemorrhage ) brain tumor complicate seizure history anoxic brain injury thirddegree burn total body surface area ( TBSA ) burn great 20 % chronic benzodiazepine ( clonazepam : lorazepam : diazepam approximately 4:8:40 mg per day ) 7 consecutive day taper history chronic delirium attributable cause anticipate transfer low level care within 24 hour admit polysubstance overdose ( determined initial drug toxicity screening ) recent exposure ( prior 7 day ) proconvulsant medication ( identify via medication history available urine drug screen ) i.e . tricyclic antidepressant , bupropion child , incarcerated individual , pregnant woman unable provide consent legally authorize representative unable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>